Retraction: Indirect recruitment of a CD40 signaling pathway in dendritic cells by B7-DC cross-linking antibody modulates T cell functions
- PMID: 20221242
- PMCID: PMC2832659
- DOI: 10.1371/annotation/36ac4b2c-cf27-41d9-90e2-e5d58d307896
Retraction: Indirect recruitment of a CD40 signaling pathway in dendritic cells by B7-DC cross-linking antibody modulates T cell functions
Conflict of interest statement
Retraction of
-
Indirect recruitment of a CD40 signaling pathway in dendritic cells by B7-DC cross-linking antibody modulates T cell functions.PLoS One. 2009;4(4):e5373. doi: 10.1371/journal.pone.0005373. Epub 2009 Apr 28. PLoS One. 2009. Retraction in: PLoS One. 2010 Mar 03;5(3). doi: 10.1371/annotation/36ac4b2c-cf27-41d9-90e2-e5d58d307896. PMID: 19399172 Free PMC article. Retracted.
Similar articles
-
Immunotherapeutic potential of B7-DC (PD-L2) cross-linking antibody in conferring antitumor immunity.Cancer Res. 2004 Jul 15;64(14):4965-72. doi: 10.1158/0008-5472.CAN-03-3025. Cancer Res. 2004. Retraction in: Cancer Res. 2010 Nov 15;70(22):9528. doi: 10.1158/0008-5472.CAN-10-3461. PMID: 15256470 Retracted.
-
Dendritic cells activated by cross-linking B7-DC (PD-L2) block inflammatory airway disease.J Allergy Clin Immunol. 2005 Sep;116(3):668-74. doi: 10.1016/j.jaci.2005.04.038. J Allergy Clin Immunol. 2005. Retraction in: J Allergy Clin Immunol. 2010 May;125(5):1173. PMID: 16159641 Retracted.
-
CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.Cancer Res. 2001 Dec 15;61(24):8787-93. Cancer Res. 2001. PMID: 11751400
-
Human dendritic cells activate T lymphocytes via a CD40: CD40 ligand-dependent pathway.Eur J Immunol. 1996 Jun;26(6):1204-10. doi: 10.1002/eji.1830260603. Eur J Immunol. 1996. PMID: 8647193
-
Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation.J Immunol. 1997 Jun 15;158(12):5676-84. J Immunol. 1997. PMID: 9190916
Cited by
-
Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity.PLoS One. 2010 Jun 21;5(6):e11216. doi: 10.1371/journal.pone.0011216. PLoS One. 2010. PMID: 20574522 Free PMC article.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials